# NSC-640358 acts as RXRα ligand to promote TNFα-mediated apoptosis of cancer cell

## TL;DR

A new compound, NSC-640358, acts as an RXRα ligand to promote cancer cell death by targeting RXRα and its truncated form tRXRα.

## Contribution

NSC-640358 is a novel RXRα ligand with a unique binding mode that indirectly regulates TR3 activity and induces cancer cell apoptosis.

## Key findings

- NSC-640358 binds to RXRα and inhibits transactivation of RXRα homodimer and RXRα/TR3 heterodimer.
- N-6 induces TNFα-mediated apoptosis in cancer cells by inhibiting AKT activation and tRXRα/p85α complex formation.
- The compound forms π–π stacking interactions with Trp305 and Phe313 in RXRα, indicating a distinct binding mode.

## Abstract

Retinoid X receptor α (RXRα) and its N-terminally truncated version tRXRα play important roles in tumorigenesis, while some RXRα ligands possess potent anti-cancer activities by targeting and modulating the tumorigenic effects of RXRα and tRXRα. Here we describe NSC-640358 (N-6), a thiazolyl-pyrazole derived compound, acts as a selective RXRα ligand to promote TNFα-mediated apoptosis of cancer cell. N-6 binds to RXRα and inhibits the transactivation of RXRα homodimer and RXRα/TR3 heterodimer. Using mutational analysis and computational study, we determine that Arg316 in RXRα, essential for 9-cis-retinoic acid binding and activating RXRα transactivation, is not required for antagonist effects of N-6, whereas Trp305 and Phe313 are crucial for N-6 binding to RXRα by forming extra π–π stacking interactions with N-6, indicating a distinct RXRα binding mode of N-6. N-6 inhibits TR3-stimulated transactivation of Gal4-DBD-RXRα-LBD by binding to the ligand binding pocket of RXRα-LBD, suggesting a strategy to regulate TR3 activity indirectly by using small molecules to target its interacting partner RXRα. For its physiological activities, we show that N-6 strongly inhibits tumor necrosis factor α (TNFα)-induced AKT activation and stimulates TNFα-mediated apoptosis in cancer cells in an RXRα/tRXRα dependent manner. The inhibition of TNFα-induced tRXRα/p85α complex formation by N-6 implies that N-6 targets tRXRα to inhibit TNFα-induced AKT activation and to induce cancer cell apoptosis. Together, our data illustrate a new RXRα ligand with a unique RXRα binding mode and the abilities to regulate TR3 activity indirectly and to induce TNFα-mediated cancer cell apoptosis by targeting RXRα/tRXRα.